Ashland Pharmaceuticals plasdone™ s-630 ultra copovidone

Ashland webinar series:
advancing solubility solutions - enhancing solubility series

chapter 1 - mastering solubility: strategies, challenges, and advanced technologies


EMEA/APAC: Wednesday, 1:00 p.m. CET - 16th October 24
NA/LATAM: Thursday, 10:00 a.m. EDT - 17th October 24

Improving solubility and enhancing bioavailability poses significant challenges in drug development. Early-stage identification of the most suitable approach among a diverse set of methodologies is crucial for drug improvement.

We will discuss formulation-based techniques based on polymers, processes, and limitations, demonstrate various approaches that facilitate enhanced drug solubility and bioavailability, optimal drug-polymer formulation, and improved pharmacokinetics.

Join us to learn about a comprehensive solution package using plasdone™ s-630 ultra copovidone, the optimized grade as a leading amorphous solid dispersed solubilizer for hot melt extrusion process.

key learning objectives:

  • understand the impact of poor solubility on drug development
  • explore innovative formulation approaches to enhance solubility
  • identify key technologies driving solubility improvement: critical attributes of materials and process equipment
  • in-depth analytics of hot melt extrusion, which offers a more sustainable alternative to spray-drying when producing amorphous solid dispersions
  • understanding critical, solid state formulation design and HME process optimization of the copovidone-drug interaction patterns

presenter information:

Fengyuan (George) Yang
PhD, Principal Scientist – Ashland

Dr. Fengyuan (George) Yang is a research scientist at Ashland. Before joining Ashland, he was an associate scientist/Post Doc at Merck & Co. He received his B.S. and M.S. degrees in polymer science and engineering from Beijing University of Chemical Technology, and his Ph.D. in Materials Science and Engineering from The Johns Hopkins University. His research interest is the application of polymers on developing functional materials. Recently, he is actively working on the application of polymeric excipients to better formulation and therapeutic performance. In the past few years, Dr. Yang has published 2 book chapters, ~30 papers in peer-reviewed journals and contributed ~30 presentations or posters to scientific conferences.

 

 

Ashish Punia
PhD, Principal Scientist: Material & Biophysical Characterization – Merck & Co., Inc.

Ashish Punia is a Principal Scientist in the Materials and Biophysical Characterization Group at Merck & Co., Inc., Rahway NJ. Prior to joining Merck, he received his PhD and MPhil in Chemistry from The Graduate Center, the City University of New York. He works as a material characterization lead on drug product development teams and supports physico-chemical understanding of drug substance and drug product formulations. His research interests include amorphous solid dispersions, solid-state characterization, implant formulations, lyophilization, and mechanistic understanding of drug-excipient interactions.

 

register for webinar

Fill out the form below to register for this webinar. You will receive follow up emails as reminders before the event.

By checking the subscribe box and submitting this form, I agree to my email address being stored and used to receive promotional emails from Ashland, and I acknowledge that I have read and understand the Ashland privacy policy.